NanoViricides Story

<div class='circular--portrait' style='background:#9CBEFD;color: #ffffff;font-size:4em;'>NI</div>
NNVC -- USA Stock  

USD 4.55  0.02  0.44%

As many millenniums are trying to avoid healthcare space, it makes sense to go over NanoViricides Inc NEW a little further and try to understand its current market patterns. We will evaluate why we are still confident in anticipation of a recovery. Is current NanoViricides NEW value sustainable? We will go over the entity valuation drivers to give you a better outlook on taking a position in it.
Published over three weeks ago
View all stories for NanoViricides Inc | View All Stories
Our prognosis on NanoViricides Inc (NYSEMKT:NNVC) to bounce back in September
This firm currently holds 1.18 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the firm is not taking enough advantage from borrowing. The company has a current ratio of 2.85, suggesting that it is liquid enough and is able to pay its financial obligations when due. We provide investment recommendation to complement the last-minute expert consensus on NanoViricides Inc NEW. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of NanoViricides Inc NEW using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of NanoViricides NEW based exclusively on its fundamental and basic technical indicators. By analyzing NanoViricides Inc's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of NanoViricides Inc's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of NanoViricides Inc. We calculate exposure to NanoViricides Inc's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to NanoViricides Inc's related companies.

NanoViricides NEW Investment Alerts

NanoViricides investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring NanoViricides Inc NEW performance across your portfolios.Please check all investment alerts for NanoViricides

NanoViricides Inc Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare NanoViricides value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NanoViricides Inc competition to find correlations between indicators driving the intrinsic value of NanoViricides.

How NanoViricides utilizes its cash?

To perform a cash flow analysis of NanoViricides Inc, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash NanoViricides Inc is receiving and how much cash it distributes out in a given period. The NanoViricides Inc cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. NanoViricides Inc Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (6.12 Million)

Sale by Theracour Pharma Inc of 10000 shares of NanoViricides Inc

Legal trades by NanoViricides Inc insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
NanoViricides Inc NEW insider trading alert for sale of common stock by Theracour Pharma Inc, the corporate stakeholder, on 17th of April 2020. This event was filed by Nanoviricides Inc with SEC on 2009-07-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another angle On NanoViricides Inc

Net Loss for the year was (13.78 M) with profit before overhead, payroll, taxes, and interest of 0.
 2019 2020 (projected)
Total Assets15.47 M21.77 M
Accounts Payable547.95 K745.97 K

NanoViricides Inc Earnings before Tax is somewhat stable at the moment. NanoViricides Inc Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. The current value of NanoViricides Inc Earnings Before Interest Taxes and Depreciation Amortization EBITDA is -7,504,808. Furthermore, NanoViricides Inc Average Assets is increasing over the last 8 years. NanoViricides Inc Earnings before Tax is decreasing over the last 8 years. The previous year's value of NanoViricides Inc Earnings before Tax was -8,180,575. NanoViricides Inc Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. Furthermore, NanoViricides Inc Average Assets is increasing over the last 8 years.

NanoViricides Inc has 99 percent likelihood to hit $4.95 in September

Kurtosis is down to 5.57. It may suggest a possible volatility slip. NanoViricides Inc NEW is displaying above-average volatility over the selected time horizon. Investors should scrutinize NanoViricides Inc NEW independently to ensure intended market timing strategies are aligned with expectations about NanoViricides Inc volatility.

Our Conclusion on NanoViricides Inc

Whereas other companies in the biotechnology industry are either recovering or due for a correction, NanoViricides Inc may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current NanoViricides valuation and our trade advice on NanoViricides Inc is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to NanoViricides Inc.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of NanoViricides Inc NEW. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to